TABLE 3.
Derived variables following an 8-h dosing intervala (1-g dose as a 5-min i.v. infusion)
| ID | Sex | eCLCr (ml/min) |
fT>MIC (%) |
t1/2b (h) | AUCc (mg h/liter) |
Cmaxc (mg/liter) |
|||
|---|---|---|---|---|---|---|---|---|---|
| Plasma | SCT | Central | Peripheral | Central | Peripheral | ||||
| 1 | M | 58.5 | 100 | 100 | 3.69 | 303.9 | 239.0 | 141.9 | 44.3 |
| 2 | M | 48.8 | 100 | 100 | 4.31 | 368.3 | 288.6 | 167.5 | 50.1 |
| 3 | F | 97.9 | 100 | 100 | 3.58 | 249.1 | 196.5 | 84.3 | 42.1 |
| 4 | F | 135.1 | 65.3 | 76.6 | 2.30 | 163.6 | 129.1 | 118.0 | 30.5 |
| 5 | F | 45.4 | 100 | 100 | 4.77 | 384.1 | 301.8 | 125.2 | 53.4 |
| 6 | M | 60.4 | 100 | 100 | 5.52 | 495.8 | 390.1 | 150.6 | 69.9 |
| 7 | F | 84.3 | 100 | 100 | 4.18 | 309.8 | 243.9 | 103.5 | 45.5 |
| 8 | F | 115 | 88.1 | 83.5 | 2.32 | 211.5 | 167.0 | 123.0 | 45.8 |
| 9 | M | 48.4 | 100 | 100 | 4.00 | 375.8 | 295.5 | 173.3 | 55.2 |
| 10 | F | 36.9 | 100 | 100 | 5.57 | 505.5 | 397.8 | 152.6 | 71.7 |
| Median | 4.09 | 339.0 | 266.2 | 133.5 | 48.0 | ||||
| IQR | 3.61, 4.66 | 262.8, 382.0 | 207.2, 300.2 | 119.3, 152.1 | 44.6, 54.7 | ||||
Drug was administered as a 1-g dose with a 5-min i.v. infusion. Abbreviations: ID, individual; F, female; M, male; eCLCr, estimated creatinine clearance calculated from the Cockgroft-Gault formula; fT, free time; SCT, subcutaneous adipose tissue; t1/2, terminal drug half-life; AUC, area under the concentration-time curve; Cmax, maximum concentration of drug in serum; IQR, interquartile range.
Calculated according to ln(2)/{0.5 × [(k12 + k21 + k10) − SQRT((k12 + k21 + k10)2 − 4 × k21 × k10)]}, where k12 = Q/Vc; k21 = Q/Vp; k10 = CL/Vc.
Derived using the differential equation solver in NONMEM for an 8-h dosing interval after two preceding doses according to 1 g q8h (i.e., calculation is for the time following the 1-g dose given at 16 h, with two previous doses given at 0 and 8 h).